Invivyd, Inc.: directors' dealings · United States · SEC (Form 4)

About Invivyd, Inc.

Invivyd, Inc. (ticker: IVVD) is a US-listed biopharmaceutical company traded on the NASDAQ market in the United States. The company focuses on preventing serious viral infectious diseases through monoclonal antibodies, with a strategy built around viral surveillance, predictive modeling, and advanced antibody engineering. From an equity-research standpoint, Invivyd fits the profile of a specialty biotech rather than a broad platform company: its valuation is driven by clinical data, regulatory outcomes, product uptake, and the durability of its authorized assets. The company was built around a proprietary antibody-discovery and optimization approach and has historically centered its efforts on COVID-19, while also describing an ambition to expand into other high-need viral indications such as influenza. Invivyd’s INVYMAB™ platform combines state-of-the-art viral surveillance with modeling tools intended to identify and engineer antibodies that can keep pace with rapidly evolving viral threats. The business is headquartered in the United States, and its operating model is consistent with a small-cap US biotech that relies on a lean commercial organization and external regulatory milestones rather than scale manufacturing breadth. Its lead commercial product is PEMGARDA® (pemivibart), a monoclonal antibody used for prophylaxis in selected immunocompromised populations at risk from SARS-CoV-2. The pipeline also includes next-generation candidates such as VYD2311, which management has positioned as a potentially low-dose, intramuscular, scalable and longer-lasting option. Invivyd is therefore competing in a narrow but meaningful niche: protection for vulnerable patients where standard vaccination may be insufficient. Its competitive position depends less on mass-market demand and more on maintaining a differentiated profile versus other antiviral and antibody-based developers, while navigating payer coverage, physician adoption, and variant evolution. Recent company updates suggest improving commercial traction. In 2025, Invivyd reported rising PEMGARDA product revenue and highlighted continued field-force execution with broader specialty reach. The company also disclosed neutralizing activity data for PEMGARDA and VYD2311 against dominant SARS-CoV-2 variants, reinforcing the relevance of its variant-response strategy. In addition, Invivyd has advanced clinical work such as the DECLARATION program, underscoring that the story remains a mix of early commercial execution and ongoing development risk. For investors in France, Belgium, and Switzerland, the key point is that Invivyd is a high-beta biotech exposure on NASDAQ in the United States: upside can be significant if commercialization and clinical expansion continue, but the name remains highly sensitive to FDA authorization status, reimbursement, competitive pressure, and cash-burn dynamics. In the context of SEC Form 4 insider transactions, insider activity should be interpreted as secondary to these core fundamentals.